Menu

Report Library

View More

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/3/25 GSK (GSK) Zejula for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
6/3/25 Johnson & Johnson (JNJ) Akeega for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
6/3/25 Pfizer (PFE) Braftovi for Melanoma Subscribers Only Subscribers Only Subscribers Only
6/3/25 Bristol (BMY) Opdualag IV for Melanoma Subscribers Only Subscribers Only Subscribers Only
6/3/25 Pfizer (PFE) Mektovi for Melanoma Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/20/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/02/2025 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Europe)